Hengrui Pharma Reports Q1 2026 Revenue and Net Profit Growth
Hengrui Pharma announced its first quarter 2026 results, with revenue increasing by 12.98% and net profit growing by 21.78% year-over-year.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) reported on Thursday, April 22, 2026, that its revenue for the first quarter of 2026 reached RMB 8.14 billion, an increase of 12.98% compared to the same period last year. Net profit attributable to shareholders rose by 21.78% to RMB 2.28 billion.
Innovative drugs remained a key driver of growth, generating RMB 4.53 billion in revenue, up 25.75% year-over-year, and accounting for 61.69% of total pharmaceutical sales.
The company sustained its research and development investments, totaling RMB 2.22 billion in Q1 2026, representing approximately 27.32% of revenue. During the period, three innovative products and new indications were approved in China. Additionally, the company secured 26 clinical trial approvals and had 8 new drug applications accepted.
Business development has become an increasingly significant growth driver, with RMB 787 million in out-licensing revenue recognized, primarily from collaboration with GSK. Since 2023, Hengrui Pharma has completed 12 overseas business development transactions.
Hengrui Pharma remains committed to innovation and globalization, aiming to strengthen its pipeline and advance the development and commercialization of innovative therapies for patients worldwide.